Cell entry, the fundamental step in cross-species transmission of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), is initiated by the recognition of the host cell angiotensin-converting enzyme-2 (ACE2) receptor by the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2. To date, several peptides have been proposed against SARS-CoV-2 both as inhibitor agents or as detection tools that can also be attached to the surfaces of nanoparticle carriers. But owing to their natural amino acid sequences, such peptides cannot be considered as efficient therapeutic candidates from a biostability point of view. This discussion demonstrates the design strategy of synthetic nonprotein amino acid substituted peptides with enhanced biostability and binding affinity, the implication of which can make those peptides potential therapeutic agents for inhibition and simple detection tools.

中文翻译：

---

面向COVID-19治疗：基于非蛋白质氨基酸的合成肽设计方法的观点

细胞进入是SARS-CoV-2（严重急性呼吸系统综合症冠状病毒2）跨物种传播的基本步骤，是通过受体结合识别宿主细胞血管紧张素转化酶2（ACE2）受体而启动的SARS-CoV-2突突蛋白的结构域（RBD）。迄今为止，已经提出了针对SARS-CoV-2的几种肽，既可以作为抑制剂也可以作为检测工具，也可以附着在纳米载体表面上。但是由于它们的天然氨基酸序列，从生物稳定性的观点来看，这些肽不能被认为是有效的治疗候选物。该讨论展示了具有增强的生物稳定性和结合亲和力的合成非蛋白质氨基酸取代的肽的设计策略，